每经AI快讯，巨子生物(02367.HK)午后涨超6%，截至发稿，涨6.12%，报38.84港元，成交额3.76亿港 元。 ...

Core Viewpoint - The company, 巨子生物, plans to repurchase shares as the current stock price is perceived to be below its intrinsic value, not reflecting the business prospects and asset value adequately [1] Group 1: Share Repurchase Announcement - 巨子生物's share price increased by over 6%, reaching 38.84 HKD with a trading volume of 376 million HKD [1] - The company announced a plan to exercise its share repurchase authorization to buy back up to 103.6 million shares, which is 10% of the issued shares excluding treasury shares [1] - The board believes that the repurchase plan is in the best interest of the company and its shareholders, serving as an effective measure for capital management and optimizing capital structure [1]

董事会认为，当前股价低于公司内在价值，未充分反映业务前景及资产价值，回购计划符合公司及股东 整体最佳利益，是资本管理及优化资本结构的有效措施。回购计划将遵守相关法规及授权，购回股份将 适时予以注销及/或持作库存股份。 智通财经APP获悉，巨子生物(02367)午后涨超6%，截至发稿，涨6.12%，报38.84港元，成交额3.76亿港 元。 消息面上，巨子生物午间公告，其计划行使回购股份授权，以购回公司股份。根据回购股份授权，公司 获准购回不超过1.036亿股股份，即已发行股份数目(不包括库存股份)的10%。 ...

智通财经APP讯，巨子生物(02367)发布公告，内容有关(其中包括)建议授出回购股份的一般授权。董事 会谨此宣布，其计划行使由股东根据于2025年6月13日的公司股东周年大会通过的决议案向董事授出的 一般授权下的权力，以购回公司股份。根据回购股份授权，公司获准购回不超过1.04亿股股份，即于股 东周年大会通过决议案之日已发行股份数目(不包括库存股份)的10%。该授权将于以下各项的最早发生 时届满：(i)公司下届股东周年大会结束时，或(ii)章程细则或其他适用法例规定公司下届股东周年大会 须予举行期限届满之日，或(iii)回购股份授权经由股东在股东大会上通过普通决议案撤销或修订之日。 ...

巨子生物(02367)发布公告，内容有关(其中包括)建议授出回购股份的一般授权。董事会谨此宣布，其计 划行使由股东根据于2025年6月13日的公司股东周年大会通过的决议案向董事授出的一般授权下的权 力，以购回公司股份。根据回购股份授权，公司获准购回不超过1.04亿股股份，即于股东周年大会通过 决议案之日已发行股份数目(不包括库存股份)的10%。该授权将于以下各项的最早发生时届满：(i)公司 下届股东周年大会结束时，或(ii)章程细则或其他适用法例规定公司下届股东周年大会须予举行期限届 满之日，或(iii)回购股份授权经由股东在股东大会上通过普通决议案撤销或修订之日。 ...

公司拟使用自有资金为上述股份回购计划提供资金，且公司预计实施该等计划将不会对集团的营运资金 状况产生重大不利影响。董事会认为当前股价低于其内在价值，并未充分反映公司的业务前景及资产价 值。股份回购计划反映董事会及管理层团队对集团的长期策略及增长充满信心。此外，股份回购计划也 将提高每股盈利等财务指标。董事会认为股份回购计划符合公司及股东的整体最佳利益，是资本管理及 优化资本结构的有效措施。 格隆汇12月2日丨巨子生物(02367.HK)宣布，其计划行使由股东根据于2025年6月13日的公司股东周年大 会通过的决议案向董事授出的一般授权下的权力，以购回公司股份。根据回购股份授权，公司获准购回 不超过103,590,400股股份，即于股东周年大会通过决议案之日已发行股份数目(不包括库存股份)的 10%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 GIANT BIOGENE HOLDING CO., LTD 巨子生物控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 獲 豁 免 有 限 公 司） （股 份 代 號：2367） 自願性公告 擬根據回購股份授權回購股份 本公告乃由巨子生物控股有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 自 願 作 出。 – 1 – 本 公 司 擬 使 用 自 有 資 金 為 上 述 股 份 回 購 計 劃 提 供 資 金，且 本 公 司 預 計 實 施 該 等 計 劃 將 不 會 對 本 集 團 的 營 運 資 金 狀 況 產 生 重 大 不 利 影 響。董 事 會 認 為 當 前 股 價 低 於 其 內 在 價 值，並 未 充 分 反 映 本 公 司 的 業 務 前 景 及 資 產 價 值。股 份 回 購 計 劃 反 映 董 事 會 ...

Core Viewpoint - The acquisition of 16.87 million shares of Sanrenxing by Yan Jianya, the chairman of Juzhi Biotechnology, positions him as the second-largest shareholder of the company, enhancing its strategic investment landscape [1][2]. Group 1: Share Transfer Details - The share transfer agreement involves the transfer of 16.87 million unrestricted shares, representing 8% of Sanrenxing's total equity, from the controlling shareholder to Yan Jianya [1]. - The transfer price is set at 26.76 yuan per share, totaling approximately 450 million yuan, which is slightly below the current market price of Sanrenxing [2]. Group 2: Yan Jianya's Background and Strategic Importance - Yan Jianya is recognized as a prominent entrepreneur and seasoned industrial investor, currently serving as the chairman of Triangular Defense and the chairman of Juzhi Biotechnology [2]. - His investment spans various sectors, including aerospace, advanced equipment manufacturing, new materials, biotechnology, and consumer goods, indicating a broad industry expertise [2][3]. Group 3: Sanrenxing's Business and Future Plans - Sanrenxing specializes in integrated marketing services within the advertising and media sector and has previously collaborated with Juzhi Biotechnology [3]. - The company aims to leverage strategic shareholder resources to enhance its business ecosystem, explore new industry avenues, and sustain growth [3]. Group 4: Previous Investments and Financial Performance - Sanrenxing has successfully exited its investment in Juzhi Biotechnology, realizing a profit of approximately 15.32 million yuan from a 200 million yuan stock sale [3]. - The company has also invested in other military-industrial chain enterprises, indicating a diversified investment strategy [3].

Core Viewpoint - The announcement by Sanrenxing (605168.SH) regarding the transfer of shares to Yan Jianya highlights a significant change in the company's ownership structure, with Yan becoming the second-largest shareholder after the transaction [1] Group 1: Share Transfer Details - Yan Jianya acquired approximately 16,865,359 shares for a total of about 451 million yuan, representing 8.00% of the company's total equity [1] - The share transfer price was set at 26.76 yuan per share, based on the closing price of the trading day prior to the signing and aligned with the lower limit of block trading prices [1] - Post-transaction, Yan Jianya will become the controlling shareholder and the second-largest shareholder outside of the company's concerted actions [1] Group 2: Yan Jianya's Background - Yan Jianya is a well-known entrepreneur and seasoned industry investor, currently serving as the chairman of listed company Triangle Defense and the chairman of the board of Juzhi Biotechnology [1] - His business interests span multiple sectors, including aerospace and military, advanced manufacturing, new materials, and biotechnology [1] - Yan and his concerted actions hold a total of 15.18% of shares in Triangle Defense and 55.34% in Juzhi Biotechnology, indicating significant equity stakes [1]

Core Insights - The article discusses the rising demand for sensitive skin care products in China, driven by a significant portion of the population experiencing skin sensitivity issues, with estimates suggesting that 30% of individuals are affected [3][4][6]. - The sensitive skin care market in China is projected to reach a scale of 66.44 billion yuan by June 2025, indicating a robust growth trajectory [4]. - Domestic brands, particularly those focusing on sensitive skin, have gained substantial market share, with brands like Winona and Huaxi Biological showing remarkable growth in sales and market presence [6][11][17]. Market Dynamics - The sensitive skin care market is characterized by a high incidence of skin sensitivity, with a daily occurrence rate of 64.1% among consumers [3]. - The demand for sensitive skin care products has led to the emergence of a billion-dollar market, with brands capitalizing on the need for effective solutions [4][6]. - The competitive landscape is shifting, with domestic brands outperforming international counterparts in terms of market share, reaching nearly 49.1% by 2022 [17]. Consumer Behavior - Consumers are increasingly willing to invest in skin care products to address their skin issues, often resorting to multiple purchases and trying various products to find effective solutions [6][25]. - The article highlights the psychological impact of skin conditions on consumers, leading to a cycle of purchasing and dissatisfaction as they seek effective remedies [9][28]. - The trend of "medical beauty" is on the rise, with a growing number of individuals seeking cosmetic procedures to enhance their appearance, further fueling the demand for sensitive skin care products [8][9]. Brand Strategies - Domestic brands have shifted their strategies from affordability to premium pricing, with significant price increases observed in their product lines [20][21]. - The article notes that brands are increasingly focusing on innovation and technology to differentiate themselves in a crowded market, with a notable increase in patent applications related to sensitive skin care [32]. - Marketing strategies have evolved, with brands now emphasizing product efficacy and scientific backing rather than solely relying on influencer endorsements [32][33].